American biotech company Biogen announced the results of a phase 3 clinical trial that showed a new Alzheimer’s drug slowed the rate of cognitive decline for early onset patients by 27%. The Alzheimer’s Association (AA) called the robust study of lecanemab, which is a monoclonal antibody designed to clear clumps of amyloid protein from the […]
The post Experimental Alzheimer’s Drug Slows Mental Decline By 27% in Trial Hailed as ‘Most Encouraging to Date’ appeared first on Good News Network.
from Good News Network https://ift.tt/OxMctIN
via IFTTT
No comments:
Post a Comment